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Nanomedicine has offered new hope for cancer treatment.[1] Nanotherapeutics exhibit many
advantages over small-molecule chemotherapeutics, including diminished systemic toxicity
and improved circulation times. Unfortunately, non-uniformly leaky vasculature[2] and a
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dense interstitial structure[3] hinder their effective delivery to tumors.[4] These physiological
abnormalities make transvascular transport—movement from vessels to the interstitium—
and interstitial transport—movement through the interstitium to target cells—
heterogeneous.[4a] Hence the tumor microenvironment limits the uniform penetration of
nanotherapeutics by slowing or halting their transport through hydrodynamic and steric
hindrance.[2a,3a,5] Overcoming these physiological barriers in tumors is an outstanding
challenge for nanomedicine.
Rational design of nanotherapeutic physicochemical properties can optimize tumor
penetration by circumventing these barriers. Decreasing nanoparticle size improves delivery
to some degree, leading to longer circulation times[4c] and more rapid transport within
tumors,[4b,c] yet smaller nanoparticles have lower drug payloads and loading efficiencies.
The role of surface charge is similarly complex; cationic charge optimizes transvascular
transport in tumors[6] while neutral charge is ideal for long circulation times[7] and
interstitial transport in tumors,[8] making charge unattractive to modulate. Particle aspect
ratio can also affect diffusion rates through pores and porous media,[9] but the effects of
aspect ratio on tumor penetration are not known. We hypothesized that nanorods, through
enhanced transport across porous media, would penetrate tumors more efficiently than
nanospheres of the same effective hydrodynamic size.
To test this hypothesis, we studied whether nanospheres and nanorods with the same
diffusive transport rates in water would transport at different rates in porous media and
tumors. To this end, we designed and developed biostable colloidal quantum dot-based
nanospheres and nanorods that have tunable size but identical surface coating and charge
(Figure 1). The spectrally distinct fluorescence from the quantum dot cores in both these
nanoparticles (Supporting Information, Figure S1) allowed for real-time multiplexed in vivo
imaging with multiphoton microscopy within the same tumor. Applying this technology, we
measured transport in vitro and in vivo for a pair of nanospheres and nanorods with equal
hydrodynamic size.
We used recently developed polyethylene glycol-modified (PEG) CdSe/CdS quantum-dot
cores with spherical silica shells for the nanospheres[4c] and CdSe quantum-dot cores with
seed-grown elongated CdS shells[10] capped with a PEG layer for the nanorods. The
synthetic procedures for silica coating and PEG capping were adapted from the literature.[11]
Unlike for the case of spherical nanoparticles, aqueous solutions of stable and uniform
CdSe/CdS nanorods are difficult to obtain. Only longer PEG chains (MW 5000) provided
aqueous solutions of nanorods that could satisfy multiple criteria for in vivo imaging.[4c] To
determine the rod dimensions—including hydrodynamic aspect ratio—with PEG, we
measured the thickness of the PEG layer based on inter-rod packing distances with and
without PEG using transmission electron microscopy (TEM). We found this layer to be
approximately 5 nm, and confirmed the measurement by comparing the difference between
the hydrodynamic and inorganic sizes for spherical nanoparticles with the same PEG coating
(Figure S2 and Table S1). We then tested the particles for stability and serum adsorption at
37°C by incubating them in phosphate-buffered saline (PBS) and fetal bovine serum (FBS),
respectively. We found that both were stable and maintained their hydrodynamic size in
serum (Figure S3, S4) as expected for PEG coated particles,[12] though we could not exclude
the formation of a small protein corona.[13] We estimated particle surface charge by
measuring ζ-potentials, which were −5.9 ± 4.0 mV[4c] and −4.9 ± 6.2 mV for the
nanospheres and nanorods respectively (Figure S5).
To determine if nanorods would transport through porous media more rapidly than
nanospheres of the same hydrodynamic size, we compared 15 nm diameter by 54 nm length
rods with 35 nm diameter spheres. Both had a 33–35 nm hydrodynamic diameter, measured
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by dynamic light scattering (DLS) and fluorescence correlation spectroscopy, and therefore
had nearly identical diffusion rates in water (Table S2). We then measured transport for both
particles across porous membranes in vitro[9a] with pore diameters from 100–5000 nm
(Figure 2a). While both the nanospheres and nanorods diffused through 5000 nm pores at
the same rate, the nanorods passed through 100–400 nm pores—in the range of maximum
pore sizes in tumor vascular walls[2a]—up to an order of magnitude faster than the
nanospheres. Next, we tested transport through tumor-mimetic collagen gels[3a] for both
particles, and found that the nanorods diffused through these gels 5.3 times as fast as the
nanospheres (Figure 2b; p = 0.003, Student’s T-test, n =3).
Considering their superior transport through porous media in vitro, we tested to see if the
nanorods could penetrate tumors more effectively than the nanospheres in vivo. We
intravenously co-injected the same two 33–35 nm hydrodynamic diameter particles—
bearing different emission maxima—into female SCID mice bearing orthotopic E0771
mammary tumors in mammary fat pad windows,[14] and then intravitally imaged their
penetration in these tumors over time using multiphoton microscopy. We quantified
nanoparticle transvascular transport as transvascular mass flux per unit vascular surface area
and transvascular concentration difference (Figure 3a), also referred to as the effective
permeability.[15] We found that the nanorods penetrated tumors 4.1 times as rapidly as the
nanospheres (p =0.03, Student’s T-test, n =6).
We further measured nanoparticle distribution—a consequence of interstitial transport—
throughout tumors 1 h after injection (Figure 3b,c), quantified as the extravascular volume
fraction of each tumor that contained nanoparticles. We determined that the nanorods
penetrated to 1.7 times the volume to which the nanospheres distributed at 1 h post-injection
(p =0.01, Student’s T-test, n =6). Importantly these particles showed no difference in plasma
half-life in non-tumor bearing mice (Figure S6), indicating similar uptake and clearance
rates by the organs. We additionally found that these 14 nm diameter 55 nm length nanorods
transported into E0771 tumors nearly as rapidly as 13 nm diameter PEG-coated CdSe/CdS
quantum dots (Figure S7), suggesting that the short dimension for nanorods largely
determines transport rates across pores.
It is important to consider that even small improvements in nanotherapeutic penetration can
result in significant enhancements to therapeutic effectiveness. Preventing matrix production
in tumors with losartan, which improves probe diffusion rates by a factor of 1.6 and
nanoparticle distribution in tumors by a factor of 2, can more than double the effectiveness
of an oncolytic virus or nanoparticle therapy against tumor growth.[16] Similarly, degrading
tumor collagen with collagenase, which improves probe diffusion rates[3b] by a factor of
1.75–2 and virus distribution[5b] by a factor of 3, can more than triple the effectiveness of an
oncolytic virus against tumor growth.[5d] Finally, repairing abnormal tumor blood vessel
function through vascular normalization with anti-angiogenic agents, which improves probe
penetration in tumors[17] by a factor of 1.5, has shown great promise for improving small-
molecule chemotherapeutic effectiveness in preclinical and clinical studies.[18] A
meaningful comparison of nanosphere versus nanorod therapeutic effectiveness may prove
intractable due to the need to match size, charge, surface chemistry, drug loading, and
release kinetics. Still, considering historical data on the connection between transport rates
and therapeutic effectiveness, our results strongly suggest that nanorods will be more
effective drug carriers than nanospheres for anti-cancer therapy.
Our data show that nanoparticle shape is an important property to be explored for the design
of effective nanomedicine. Combining the in vitro and in vivo results, in which the
differences in transport rates are similar, it is likely that nanorods penetrate tumors more
rapidly than nanospheres due to improved transport through pores. Other mechanisms, such
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as alignment with bloodflow increasing the probability of convective delivery for
nanorods,[19] are very unlikely since tumors tend to have sluggish blood flow and low
transvascular fluid flux.[4a] We therefore speculate that reduced steric hindrance from and
viscous drag near vessel pore walls leads to the difference in nanosphere versus nanorod
delivery, as seems to be the case for transport across membranes with uniform pores in
vitro.[9a] Interestingly, flexible nanorods may be able to take greater advantage of this
mechanism, as they demonstrate reptation behavior that improves their transport versus rigid
rods through porous gels.[9b] Flexible rods also demonstrate superior circulation times when
compared to rigid rods, likely through enhanced evasion of phagocytosis.[20] Furthermore,
nanorods feature a larger surface/volume ratio than nanospheres, which may prove
advantageous since the addition of a targeting ligand can aid in cell binding, cell uptake, and
therapeutic effectiveness.[21] Considering these superior properties, it seems that rod shaped
nanotherapeutics—including nanotubes and nanoworms—may be far more effective for
cancer therapy than the currently approved spherical nanomedicines.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Nanospheres and nanorods designed for real-time in vivo imaging. a) Schematic
representation of nanospheres and nanorods. The PEG layer is depicted as a gray glow.
Dimensions obtained with TEM for the nanorod cores are shown (4.7 nm diameter and 44.0
length) as well as the approximate PEG-coated hydrodynamic lengths (15 nm diameter and
54 nm length). The hydrodynamic diameter range of the nanospheres and nanorods
(obtained with DLS) is also shown (33–35 nm). b) TEM images of nanospheres and
nanorods.
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Transport rates in vitro for nanospheres versus nanorods of the same hydrodynamic diameter
(33–35 nm). a) Diffusion rates across membranes with varied pore size, quantified as
permeability. Both particles pass through micrometer-range pores at the same rate, while
nanometer-range pores hinder the nanospheres more than the nanorods. b) Diffusion
coefficients in 1% collagen gels. The nanorods diffuse 5.3-times as fast as the nanospheres
(p =0.003, *).
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Transport and distribution in tumors in vivo for nanospheres versus nanorods of the same
hydrodynamic diameter (33–35 nm). a) Transvascular transport rates in orthotopic E0771
mammary tumors in mice. The nanorods are transported across vessel walls 4.1-times as fast
as the nanospheres (p =0.03, *). b) Nanoparticle distribution in orthotopic E0771 mammary
tumors in mice. The nanorods penetrate to 1.7 times the volume to which the nanospheres
distribute (p =0.01, *). c) Nanoparticle penetration in tumors. Intensities are normalized to
initial intravascular levels, and vessels are shown in black. The rods extravasate more and
penetrate deeper than the spheres. Scale bar 100 μm.
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